Press Releases
[MoneyToday] Protium Science Signs Business Agreement with SML Meditree for Clinical Trial Sample Analysis
Collaboration on Clinical Trial Sample Analysis and Analytical Method Development to Maximize Technological Synergies
Jointly Addressing Customer Needs from Drug Substance Standardization Strategies to Clinical Trial Sample Analysis
Protium Science, a subsidiary of TiumBio, announced on the 13th that it had entered into a strategic business agreement with SML Meditree on the 12th to collaborate on clinical trial sample analysis and analytical method development services.
Under the agreement, the two companies plan to jointly address customer needs ranging from drug substance standardization strategies to clinical trial sample analysis, leveraging the technologies and expertise they have accumulated in their respective fields.
Protium Science provides a range of services based on its data-driven decision-making (DDDM) platform, including end-to-end process development services required for biopharmaceutical production, from cell line development through the production of drug substances and drug products. These services cover upstream processing, purification, formulation, and analytical development. The company also provides consulting on the preparation of documents required for clinical trial applications and responses to requests for additional information from regulatory authorities.
SML Meditree is a clinical trial sample analysis institution that became independent from Samkwang Medical Laboratories in 2012. In addition to research projects, the company provides clinical trial sample analysis services in compliance with Good Clinical Laboratory Practice (GCLP) standards throughout the entire clinical development process, from Phase 1 through Phase 4. It also provides a range of solutions, including project and data management and biopharmaceutical logistics.
Yong-ho Ahn, CEO of Protium Science, said, “This collaboration with SML Meditree will serve as an opportunity for the two companies, each possessing competitive technologies in their respective fields, to maximize business synergies.”
Dong-soo Lee, CEO of SML Meditree, said, “By combining the expertise and experience of both companies, we expect to provide innovative analytical method development for biopharmaceuticals as well as precise and highly reliable clinical trial sample analysis services. This will ultimately provide significant benefits to our respective customers, and through continued collaboration, we will continue to create new value in biopharmaceutical development and clinical trials.”